Daniel Schneiderman - Oct 11, 2022 Form 4 Insider Report for Pasithea Therapeutics Corp. (KTTA)

Role
Chief Financial Officer
Signature
/s/ Daniel Schneiderman
Stock symbol
KTTA
Transactions as of
Oct 11, 2022
Transactions value $
$0
Form type
4
Date filed
10/12/2022, 08:15 PM
Previous filing
Aug 15, 2022
Next filing
Mar 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KTTA Stock Option (to acquire Common Stock) Award $0 +300K $0.00 300K Oct 11, 2022 Common Stock 300K $1.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted 300,000 stock options. The stock options have a ten-year term and vest over three years, subject to Mr. Schneiderman remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches monthly for two years thereinafter.